Author:
Nakka Parvathi,Jassi Chikondi,Chen Ming-Cheng,Liu Yi-Sheng,Liu Jer-Yuh,Yeh Chung-Min,Li Chi-Cheng,Chang Yu-Chun,Kuo Wei-Wen,Huang Chih-Yang
Funder
Ministry of Science and Technology, Taiwan
Asia University Taiwan
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Hsieh CH, Hsu HH, Shibu MA, Day CH, Bau DT, Ho CC, Lin YM, Chen MC, Wang SH, Huang CY. Down-regulation of β-catenin and the associated migration ability by Taiwanin C in arecoline and 4-NQO-induced oral cancer cells via GSK-3β activation. Mol Carcinog. 2017;56(3):1055–67.
2. Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954–64.
3. Ding X-X, Zhu Q-G, Zhang S-M, Guan L, Li T, Zhang L, Wang S-Y, Ren W-L, Chen X-M, Zhao J. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8(33):55715.
4. Huang SM, Jeng L-B, Shyu W-C, Chen H-Y. Combination treatment of pembrolizumab with DC-CIK cell therapy for Advanced hepatocellular carcinoma: a case report. Biomedicine. 2023;13(3):57–62.
5. Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 2017;7(6):1350.